Alliancebernstein L.P. Buys 272,747 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Alliancebernstein L.P. increased its holding in Thermo Fisher Scientific Inc. by 18.3%, acquiring an additional 272,747 shares, bringing its total ownership to 1,766,067 shares valued at approximately $878.8 million.
• The company recently reported earnings, with an EPS of $5.36 for the last quarter, outperforming analysts' expectations of $5.22 and marking a 2.9% year-over-year revenue growth.
• Thermo Fisher Scientific declared a quarterly dividend of $0.43 per share, with a record date of September 15th, representing an annualized dividend yield of 0.4%.

Alliancebernstein L.P. raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 18.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,766,067 shares of the medical research company's stock after purchasing an additional 272,747 shares during the quarter. Alliancebernstein L.P. owned approximately 0.47% of Thermo Fisher Scientific worth $878,795,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Mondrian Investment Partners LTD boosted its stake in shares of Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after acquiring an additional 127,357 shares during the period. GAMMA Investing LLC boosted its stake in shares of Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after acquiring an additional 877 shares during the period. Deutsche Bank AG boosted its stake in shares of Thermo Fisher Scientific by 9.5% during the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock worth $687,553,000 after acquiring an additional 114,277 shares during the period. Cetera Trust Company N.A boosted its stake in shares of Thermo Fisher Scientific by 3.3% during the 1st quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock worth $2,312,000 after acquiring an additional 150 shares during the period. Finally, Philip James Wealth Mangement LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $268,000. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,666 shares of company stock worth $13,982,763. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Down 1.2%

Shares of TMO stock opened at $486.82 on Wednesday. The stock's fifty day simple moving average is $456.01 and its 200 day simple moving average is $453.73. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The firm has a market capitalization of $183.83 billion, a P/E ratio of 28.16, a P/E/G ratio of 2.63 and a beta of 0.75. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the company posted $5.37 EPS. The business's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is 9.95%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TMO. UBS Group boosted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Evercore ISI reduced their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Finally, William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating for the company. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.